39.99
2.05 (5.40%)
| Previous Close | 37.94 |
| Open | 38.02 |
| Volume | 4,899,206 |
| Avg. Volume (3M) | 3,335,285 |
| Market Cap | 3,930,097,408 |
| Price / Earnings (Forward) | 8.34 |
| Price / Sales | 1.77 |
| Price / Book | 3.13 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | 12.37% |
| Operating Margin (TTM) | 24.56% |
| Diluted EPS (TTM) | 2.34 |
| Quarterly Revenue Growth (YOY) | 65.90% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 87.90% |
| Current Ratio (MRQ) | 4.20 |
| Operating Cash Flow (TTM) | -205.79 M |
| Levered Free Cash Flow (TTM) | -445.48 M |
| Return on Assets (TTM) | 3.77% |
| Return on Equity (TTM) | 19.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Sarepta Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 1.13 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.41% |
| % Held by Institutions | 88.92% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (Needham, 212.58%) | Buy |
| Median | 98.00 (145.06%) | |
| Low | 40.00 (HC Wainwright & Co., 0.03%) | Hold |
| Average | 90.08 (125.26%) | |
| Total | 9 Buy, 4 Hold | |
| Avg. Price @ Call | 43.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 20 May 2025 | 84.00 (110.05%) | Buy | 39.99 |
| Wells Fargo | 08 May 2025 | 100.00 (150.06%) | Buy | 36.52 |
| 11 Apr 2025 | 115.00 (187.57%) | Buy | 51.03 | |
| Cantor Fitzgerald | 07 May 2025 | 81.00 (102.55%) | Buy | 36.72 |
| 19 Mar 2025 | 163.00 (307.60%) | Buy | 79.97 | |
| Goldman Sachs | 07 May 2025 | 100.00 (150.06%) | Buy | 36.72 |
| Guggenheim | 07 May 2025 | 98.00 (145.06%) | Buy | 36.72 |
| HC Wainwright & Co. | 07 May 2025 | 40.00 (0.03%) | Hold | 36.72 |
| 16 Apr 2025 | 75.00 (87.55%) | Hold | 53.94 | |
| Morgan Stanley | 07 May 2025 | 113.00 (182.57%) | Buy | 36.72 |
| 11 Apr 2025 | 182.00 (355.11%) | Buy | 51.03 | |
| Needham | 07 May 2025 | 125.00 (212.58%) | Buy | 36.72 |
| 03 Apr 2025 | 183.00 (357.61%) | Buy | 58.61 | |
| Oppenheimer | 07 May 2025 | 123.00 (207.58%) | Buy | 36.72 |
| Piper Sandler | 07 May 2025 | 70.00 (75.04%) | Buy | 36.72 |
| 21 Apr 2025 | 110.00 (175.07%) | Buy | 55.23 | |
| RBC Capital | 07 May 2025 | 58.00 (45.04%) | Hold | 36.72 |
| 31 Mar 2025 | 87.00 (117.55%) | Hold | 63.82 | |
| Scotiabank | 20 Mar 2025 | 80.00 (100.05%) | Hold | 73.45 |
| 07 Mar 2025 | 105.00 (162.57%) | Hold | 103.03 | |
| Deutsche Bank | 19 Mar 2025 | 99.00 (147.56%) | Hold | 79.97 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BARRY RICHARD | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BARRY RICHARD | Director | 13 May 2025 | Option execute | 20,246 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |